KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) Debt to Equity (2019 - 2025)

Rigel Pharmaceuticals has reported Debt to Equity over the past 7 years, most recently at $0.21 for Q4 2025.

  • Quarterly results put Debt to Equity at $0.21 for Q4 2025, down 98.84% from a year ago — trailing twelve months through Dec 2025 was $0.21 (down 98.84% YoY), and the annual figure for FY2025 was $0.21, down 98.84%.
  • Debt to Equity for Q4 2025 was $0.21 at Rigel Pharmaceuticals, down from $0.51 in the prior quarter.
  • Over the last five years, Debt to Equity for RIGL hit a ceiling of $18.15 in Q4 2024 and a floor of -$8.11 in Q2 2022.
  • Median Debt to Equity over the past 5 years was -$0.83 (2023), compared with a mean of -$0.03.
  • Peak annual rise in Debt to Equity hit 1632.37% in 2022, while the deepest fall reached 2882.69% in 2022.
  • Rigel Pharmaceuticals' Debt to Equity stood at $0.66 in 2021, then tumbled by 541.89% to -$2.9 in 2022, then rose by 28.18% to -$2.08 in 2023, then soared by 972.31% to $18.15 in 2024, then plummeted by 98.84% to $0.21 in 2025.
  • The last three reported values for Debt to Equity were $0.21 (Q4 2025), $0.51 (Q3 2025), and $0.73 (Q2 2025) per Business Quant data.